U.S. Stocks Movement | Novartis Pharmaceuticals rises over 3% pre-market as Q2 earnings beat expectations

Golden Ten Data July 21st｜A certain exchange rose 3.77% in pre-market trading, closing at $155.2. In terms of news, the exchange announced second-quarter results that were better than market expectations. The strong performance of its new-generation anti-cancer drug offset the impact of generic drugs on its blockbuster heart medication Entresto, signaling the company's return to a growth trajectory. The financial report shows that in the second quarter, sales increased by 3% year-on-year to $14.408 billion, exceeding the expected $14.042 billion; core operating profit was $5.94 billion, surpassing the expected $5.34 billion; core earnings per share were $2.41, higher than the expected $2.13.